

No. 12-02-2009

Reimbursement of PNDF Drugs Only When Used in Hospitals with DOH-Accredited Antimicrobial Resistance Surveillance Program

Section 37 (c-1) of Republic Act 7875 as amended by RA 9241, stipulates that “Drugs for which payments will be made shall be those included in the Philippine National Drug Formulary, unless explicit exception is granted by the Corporation.” In addition, PhilHealth Circular No. 26 s-2009 provides for the use of the PNDF Volume 1, 7th edition as the main reference for PhilHealth drug reimbursement.

In line with these, page 134 of the PNDF Volume 1, 7th edition, is reiterated which states that the following drugs can only be reimbursed when used in hospitals with DOH-Accredited Antimicrobial Resistance Surveillance Program:

Generic name	Route	Pharmaceutical forms and strengths
cefepime	Inj.:	500 mg, 1 g, 2 g vial (IM/IV) (as hydrochloride)
ertapenem	Inj.:	1 g powder, vial (IM/IV) (as sodium salt)
levofloxacin	Oral: Inj.:	250 mg, 500 mg, & 750 mg tablet 5mg/mL solution for IV infusion, 100mL vial
meropenem	Inj.:	500 mg & 1 g powder, vial (IV) (as trihydrate)
piperacillin+ tazobactam	Inj.:	2 g + 250 mg per vial (as sodium salt) (IV infusion) 4 g + 500 mg per vial (as sodium salt) (IV infusion)
vancomycin	Inj.:	500 mg & 1 g vial (IV) (as hydrochloride)

Please be guided accordingly.



DR. REY B. AQUINO
President and CEO